智能聚焦 「電場導航」 TMS

09/06/2022

🍾️🎊👏

Today we at Nexstim are happy to congratulate our founding father, Risto Ilmoniemi, to his honorary doctorate from University of Helsinki. Congratulations Risto!

08/06/2022

The survival rate for glioblastoma is 22% for patients 20-44, 9% for patients 45-54, and 6% for patients 55-64, according to the American Cancer Society. On this Brain Tumor Awareness Day, we want to thank our neurosurgery partners who are working to challenge those statistics every day.

Click here to learn more about the latest advances in nTMS and tumor treatment: https://nexstim-ntms.com/tumor-awareness

30/05/2022

Live Demonstrations at our Nexstim booth at DGNC in Cologne are ongoing, come stop by our booth (no. 12):

Monday, 30 May 2022
10:45 – 11:00 / 12:30 – 12:45 / 15:45 – 16:00
Tuesday, 31 May 2022
9:00 – 9:15 / 10:30 – 10:45 / 13:45 – 14:00 / 16:15 – 16:30
Wednesday, 1 June 2022
9:15 – 9:30 / 10:30 – 10:45 / 11:45 – 12:00

26/05/2022

Nice to see so many Nexstim users presenting their research at this year’s DGNC in Germany. If you are curious what new developments are being made in the field of nTMS, don’t miss out on the following talks: https://nexstim-ntms.com/dgnc-nexstim-tms-lectures

16/05/2022

Last week the Extended Advanced Course Consciousness was held in Venice, Italy and we were excited to see researchers presenting on an algorithm allowing for real-time monitoring of TMS-evoked potentials as well as interesting new applications in which TMS-EEG could be used. If you are curious about TMS-EEG and want to learn more, we have curated some information on our website: https://nexstim-ntms.com/tms-eeg

To the event page: https://www.neurosas.org/advanced-courses-venice/overview/

-eeg

18/03/2022

Thank you to all who visited our booth at the Svenska Psykiatrikongressen in Stockholm! It was great to meet so many of you in person and discuss about the possibilities for navigated TMS in depression treatment in Sweden. If you couldn’t make the event, more information about nTMS therapy for depression patients can be found on our website: https://nexstim-ntms.com/depression-spk

10/03/2022

We are happy to announce our next Nexstim Podium Webinar with Prof. Jean-Pascal Lefaucheur on March 23!

Register for the event following this Link: https://nexstim-ntms.com/pain-lefaucheur

08/03/2022

Prof. Sandro Krieg presents today on the advantages of integrating nTMS into the clinical workflow, including the impact on preoperative clinical decision making and intraoperative guidance.

08/03/2022

Aalto-yliopiston kehittämä algoritmi mahdollistaa aivojen täsmästimulaation ja avaa uusia mahdollisuuksia esimerkiksi masennuksen ja kivun hoitoon.

08/03/2022

Did you know that young patients may not have the same access to non-invasive pre-surgical diagnostic tools as adults?

Nexstim’s non-invasive nTMS mapping overcomes many limitations of other brain mapping modalities and has even been done on infants under 1 yr. Additionally, pre-operative nTMS may help avoid putting some children through invasive EEG-monitoring (Narayana et al., 2021: https://nexstim-ntms.com/frontiersin-presurgical-nTMS-mapping)

Learn more about the latest advancements in nTMS for pediatrics here: https://nexstim-ntms.com/advances-in-pediatrics

08/03/2022

Today is International Epilepsy Awareness Day.

While 50 million people worldwide have epilepsy, only 70% respond to anti-epileptic medication. Nexstim is devoted to help patients and clinicians access critical information to safely navigate treatment options.

Learn more about clinicians are using nTMS to elevate the standard of care for their youngest epilepsy patients here: https://bit.ly/ntms-in-pediatrics

08/03/2022

Nexstim Plc to license technology to US-based medical technology company Magnus Medical, Inc. for the treatment of neuropsychiatric disorders. The estimated total value of the license agreement is approximately USD 19 million (~EUR 17 million). The license agreement offers both Nexstim and Magnus Medical unique operative opportunities, and we make the announcement about the agreement with great proudness. More information about the agreement in full release to be found at https://nexstim.com/news-and-events/news/press-release/news/nexstim-plc-to-license-technology-to-us-based-medical-technology-company-magnus-medical-inc-for-th/

04/02/2022

BackgroundPerioperative assessment of language function in brain tumor patients commonly relies on administration of object naming during stimulation mapping. Ample research, however, points to the benefit of adding verb tasks to the testing paradigm in order to delineate and preserve postoperative....

04/02/2022

We have released an update on the clinical outcomes of over 300 patients in our patient registry: of the MDD patients treated, remission rate continued to be over 50% and more than 76% of the patients had obtained a clinical response.
https://nexstim.com/news-and-events/news/press-release/news/nexstim-reaches-over-300-completed-treatment-sessions-continues-to-report-a-remission-rate-greater/

05/11/2021

We are happy to announce our cooperation with the Recuror private psychiatry centre, bringing personalised treatments for difficult neurological disorders better available in the Finnish private sector.

See our press release (available in English and Finnish) on our website: https://nexstim.com/news-and-events/news/press-release/news/nexstim-engages-in-cooperation-with-private-finnish-clinic-and-makes-progress-in-its-strategic-goals/

03/11/2021

Neuroteknologian hyödyntäminen on jo arkipäivää sairaanhoidossa. Esimerkiksi masennusta ja kipupotilaita hoidetaan päivittäin magneettistimulaatiolla. Pienen pienet neurojyvät ovat teknologian seuraava sukupolvi.

02/11/2021

The Modern Age of Non-Invasive Mental Health Innovations: Transcranial Magnetic Stimulation Written By: Jessica Connell-Glynn | Dr. Robert L...